State Street’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

State Street’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,851	Closed	-$15K	–	4344
2024 Q4	$15K	Hold	2,851	–	–	﹤0.01%	4254
2024 Q3	$40.8K	Hold	2,851	–	–	﹤0.01%	4131
2024 Q2	$46.2K	Hold	2,851	–	–	﹤0.01%	4156
2024 Q1	$289K	Buy	2,851 +694	+32%	+$43.9K	﹤0.01%	3789
2023 Q4	$50.9K	Hold	2,157	–	–	﹤0.01%	4196
2023 Q3	$44.4K	Hold	2,157	–	–	﹤0.01%	4315
2023 Q2	$56.1K	Hold	2,157	–	–	﹤0.01%	4387
2023 Q1	$44.9K	Hold	2,157	–	–	﹤0.01%	4528
2022 Q4	$44K	Hold	2,157	–	–	﹤0.01%	4586
2022 Q3	$60K	Hold	2,157	–	–	﹤0.01%	4619
2022 Q2	$57K	Sell	2,157 -7,818	-78%	-$348K	﹤0.01%	4698
2022 Q1	$798K	Buy	9,975 +1,138	+13%	+$141K	﹤0.01%	3881
2021 Q4	$1.8M	Buy	8,837 +932	+12%	+$233K	﹤0.01%	3669
2021 Q3	$2.56M	Buy	7,905 +3,724	+89%	+$1.09M	﹤0.01%	3544
2021 Q2	$1.09M	Buy	+4,181	New	+$1.27M	﹤0.01%	3653

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street's VINC Position: Q1 2025 in Review

State Street sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q1 2025, closing a stake of 2,851 shares — an estimated $15K sold.

State Street first reported a position in VINC in Q2 2021 and held it in 15 quarters. The position peaked at $2.56M in Q3 2021. 14 funds tracked by Wall St. Rank hold VINC as of Q1 2025.

State Street reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
State Street sold 2,851 Vincerx Pharma, Inc. Common Stock shares in Q1 2025, an estimated $15K.
State Street first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 15 quarters.
State Street's Vincerx Pharma, Inc. Common Stock position peaked at $2.56M in Q3 2021.
14 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q1 2025.

Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.